CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

F. Birzele, E. Voss, A. Nopora, K. Honold, F. Heil, S. Lohmann, H. Verheul, C. Le Tourneau, J.P. Delord, C Van Herpen, D. Mahalingam, A.L. Coveler, V. Meresse, S. Weigand, V. Runza, M. Cannarile

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2753-2762
JournalClinical Cancer Research
Volume21
Issue number12
DOIs
Publication statusPublished - 2015

Cite this

Birzele, F., Voss, E., Nopora, A., Honold, K., Heil, F., Lohmann, S., ... Cannarile, M. (2015). CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clinical Cancer Research, 21(12), 2753-2762. https://doi.org/10.1158/1078-0432.CCR-14-2141
Birzele, F. ; Voss, E. ; Nopora, A. ; Honold, K. ; Heil, F. ; Lohmann, S. ; Verheul, H. ; Le Tourneau, C. ; Delord, J.P. ; Van Herpen, C ; Mahalingam, D. ; Coveler, A.L. ; Meresse, V. ; Weigand, S. ; Runza, V. ; Cannarile, M. / CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. In: Clinical Cancer Research. 2015 ; Vol. 21, No. 12. pp. 2753-2762.
@article{4ea41c889a3a4e809555bc82700b7005,
title = "CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients",
author = "F. Birzele and E. Voss and A. Nopora and K. Honold and F. Heil and S. Lohmann and H. Verheul and {Le Tourneau}, C. and J.P. Delord and {Van Herpen}, C and D. Mahalingam and A.L. Coveler and V. Meresse and S. Weigand and V. Runza and M. Cannarile",
year = "2015",
doi = "10.1158/1078-0432.CCR-14-2141",
language = "Undefined/Unknown",
volume = "21",
pages = "2753--2762",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

Birzele, F, Voss, E, Nopora, A, Honold, K, Heil, F, Lohmann, S, Verheul, H, Le Tourneau, C, Delord, JP, Van Herpen, C, Mahalingam, D, Coveler, AL, Meresse, V, Weigand, S, Runza, V & Cannarile, M 2015, 'CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients' Clinical Cancer Research, vol. 21, no. 12, pp. 2753-2762. https://doi.org/10.1158/1078-0432.CCR-14-2141

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. / Birzele, F.; Voss, E.; Nopora, A.; Honold, K.; Heil, F.; Lohmann, S.; Verheul, H.; Le Tourneau, C.; Delord, J.P.; Van Herpen, C; Mahalingam, D.; Coveler, A.L.; Meresse, V.; Weigand, S.; Runza, V.; Cannarile, M.

In: Clinical Cancer Research, Vol. 21, No. 12, 2015, p. 2753-2762.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

AU - Birzele, F.

AU - Voss, E.

AU - Nopora, A.

AU - Honold, K.

AU - Heil, F.

AU - Lohmann, S.

AU - Verheul, H.

AU - Le Tourneau, C.

AU - Delord, J.P.

AU - Van Herpen, C

AU - Mahalingam, D.

AU - Coveler, A.L.

AU - Meresse, V.

AU - Weigand, S.

AU - Runza, V.

AU - Cannarile, M.

PY - 2015

Y1 - 2015

U2 - 10.1158/1078-0432.CCR-14-2141

DO - 10.1158/1078-0432.CCR-14-2141

M3 - Article

VL - 21

SP - 2753

EP - 2762

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -